Pharmacogenomic terminology

1234567891011121314151617181920
Across
  1. 3. HIV drug for which all patients undergo a genetic test prior to administration
  2. 6. A precursor (forerunner) of a drug needs to undergo chemical conversion by metabolic processes before becoming an active pharmacological agent
  3. 8. Variants in this gene can cause severe reactions in response to carbamazepine and abcavir
  4. 9. An unintended, harmful reaction to medicines
  5. 15. An individual’s collection of genes
  6. 16. The biochemical and physiological effects of drugs, particularly those that define the drugs mechanism of action on the body
  7. 19. Two normally functioning alleles and therefore have normal enzyme activity
  8. 20. The basic physical unit of inheritance
Down
  1. 1. A study to assess common genetic variations across the entire genome of a large population of individuals in order to study whether any of the investigated variations is associated with a phenotype of interest
  2. 2. A gene predicted to be associated with a particular trait e.g disease, adverse reaction to a drug
  3. 4. A single nucleotide locus with two or more naturally occurring alleles defined by a single base pair substitution
  4. 5. A variant that has two or more alleles and is present at a frequency of at least 1% of the population
  5. 7. Can cause respiratory depression in some babies
  6. 10. The absorption, distribution, metabolism, and excretion (ADME) of bioactive drugs following their administration
  7. 11. A group of enzymes involved in drug metabolism and found in high levels in the liver
  8. 12. A collection of genetic variants, such as SNPs, that always travel together (are inherited together) on the same individual allele
  9. 13. Well know anticoagulant that causes severe side affects in certain individuals
  10. 14. Two non-functional alleles and therefore have little to no enzyme activity
  11. 17. When two different alleles are present on the chromosome pair
  12. 18. Part of the genome formed by DNA sequences that encode genes
  13. 19. Maximum beneficial or therapeutic response that a drug can produce